

SPEAKER INTRODUCTION (In order of appearance)



Prof. Hong Wu
Peking University; Dean, School of Life Sciences

Dr. Hong Wu is Professor and Dean of School of Life Sciences, Peking University, and Senior Investigator of Peking-Tsinghua Center for Life Sciences. Before returning to China, Dr. Hong Wu was David Geffen Professor of Molecular and Medical Pharmacology and Director of Institute for Molecular Medicine, David Geffen School of Medicine at UCLA. Dr. Wu received her medical training from Beijing Medical College, China, and Ph.D. degree in Biological Chemistry from Harvard Medical School. After postdoctoral training as a Damon Runyon-Walter Winchell postdoctoral fellow at the Whitehead Institute for Biomedical Research, MIT, She joined UCLA as a faculty member. A major research focus of Dr. Wu's laboratory is to study the molecular mechanism of PTEN tumor suppressor controlled tumorigenesis. By generating tissue-specific PTEN deficient animal models, Dr. Wu's laboratory elucidated the important role of PTEN in regulating stem cell self-renewal, proliferation, and survival, as well as its roles in controlling the PI3K pathway. These models have been used for pre-clinical studies of new therapeutic agents and for identifying biomarkers for human cancers.



Prof. Dr. Hanno Wild
Bayer; Senior Vice President, Head of Candidate Generation & External Innovation, Drug Discovery

Prof. Dr. Hanno Wild is currently Head of Candidate Generation & External Innovation function of Drug Discovery, Bayer Pharmaceuticals, with major locations in Wuppertal and Berlin, Germany. In this role, he is responsible for the identification and optimization of low-molecular-weight drug candidates for all therapeutic research groups, for the chemistry of antibody-drug conjugates and antibody-thorium conjugates for cancer therapy, as well as for the generation and management of external partnerships and alliances. Prof. Wild, trained in chemistry, holds a Ph.D. as well as an honorary professorship of the University Bonn. After his studies of chemistry in Bonn and a postdoc fellowship (University of California, Irvine, USA, Prof. Larry Overman), Prof. Wild started his career with Bayer as a Medicinal Chemist in 1988. From 1994 to 1996 he was a delegate at the Bayer Pharma Research Center in West Haven, Connecticut, USA, focusing on cancer research including the project leading to the marketed product Nexavar. Soon after his return to the Wuppertal Research Center he assumed the position as section head at the Medicinal Chemistry Department of Bayer, responsible for the indication "Atherosclerosis" as well as for several collaborations in the field of compound acquisition and chem-/bioinformatics. From 2002 to 2006 he was Vice President and Head of the Medicinal Chemistry Department of Bayer HealthCare in Wuppertal, Germany and from 2006 to 2007, Prof. Wild served as Senior Vice President Discovery Europe, Bayer HealthCare before taking over his current role.



Prof. Jianbo Wang
Peking University; College of Chemistry and
Molecular Engineering

Current Research Interest

- Catalytic metal carbene transformations
- Organic radical reactions
- Transition-metal-free reactions

Education

- BEng, 1983, Nanjing University of Science and Technology
- PhD, 1990, Hokkaido University
- PostDoc, 1990-1993, University of Geneva
- PostDoc, 1993-1995, University of Wisconsin-Madison



Prof. Yan Zhang
Peking University; Institute of Molecular Medicine

Current Research Interest

- Cardiomyocyte death and cardioprotection
- Metabolic disorders and its cardiovascular complications

Education

- BSc, 2003, Peking University
- PhD, 2008, Peking University
- PostDoc, 2007, University of Medicine and Dentistry of New Jersey
- PostDoc, 2010, Peking University



Dr. Hans Lindner
Bayer; Vice President, Head of Global External
Innovation & Alliances, Drug Discovery

In this role, which he assumed in 2014, he is overseeing activities for collaborations and external innovation models for early drug discovery and development. Hans is a registered pharmacist with a doctorate degree in pharmaceutical technology from

university of Kiel. He has had a number of different positions in Pharmaceutical Industry. He started 1994 as formulation scientist at Arzneimittelwerk Dresden GmbH, then joining Ferring Pharmaceuticals where he finally led pharmaceutical development in Copenhagen. In 2004 he took over pharmaceutical development at Schwarz Pharma, Germany. After merger with UCB S.A. he was directing late phase pharmaceutical product development. In 2008, he joined Bayer as head of global pharmaceutical development, later setting up a new unit dedicated to external work. Hans is member of the editorial board of the European Journal of Pharmaceutics and Biopharmaceutics, member of various professional associations and past vice president of the European Association Pharma Biotechnology (EAPB).



Prof. Dr. Andreas Busch

**Bayer; Head of Drug Discovery and Animal Health,
Member of Pharmaceuticals Executive Committee**

Professor Busch has been Head of Drug Discovery (research & early development pharmaceuticals) since February 1, 2007. The research function of the Animal Health Division has been integrated into Drug Discovery as of March 1, 2011. From March 1, 2011 to December 31, 2015 he has been a member of the Bayer HealthCare Executive Committee and has reported to the Head of Bayer HealthCare. As of January 1, 2016 he is a member of the Bayer Pharmaceuticals Executive Committee and reports in his capacity to the Head of Bayer Pharmaceuticals. Professor Busch studied pharmacy at Johann Wolfgang Goethe University in Frankfurt am Main. After earning a doctorate in pharmacology in 1989, he worked at various research institutes in Germany and the United States. Professor Busch was appointed Head of Cardiovascular Research at Hoechst Marion Roussel in 1997 and at Aventis in 1999. At Sanofi-Aventis, Busch led the cardiovascular research efforts at the research sites Frankfurt and Paris. Professor Busch joined Bayer HealthCare in 2005, where he initially worked as Head of Pharmaceutical Research Europe at the Wuppertal site. He was appointed Head of Research and early Drug Development at Bayer HealthCare in January 2006.



Prof. Demin Zhou

**Peking University Health Science Center; School of
Pharmaceutical Sciences**

Current Research Interest

Integration of chemistry and biology for drug discovery:

- Identification of natural products and derivatives for manipulation of virus-host recognition
- Site-specific modification of endogenous molecules for development of bio-therapeutics

Education

- BS, 1990, Beijing Medical University
- PhD, 1996, Jointed by Beijing Medical University and University of Tsukuba, Japan
- PostDoc, 1999, University of California at Berkeley



Prof. Xiaodong Su

Peking University; School of Life Sciences

Current Research Interest

- Single molecule biophysics and NGS (next-generation sequencing) related technique developments, particularly cancer genomics
- Structure-based rational drug design, protein-DNA interaction and innate immunity

Education

- BSc, 1985 Peking University, China
- PhD, 1994 Karolinska Institute, Sweden



Prof. Junmin Quan
Peking University Shenzhen Graduate School;
School of Chemical Biology & Biotechnology

Current Research Interest

- Structural biology in cell fate regulations
- Cancer Immunotherapy

Education

- BSc, 1997, Peking University
- MSc, 2000, Sun Yat-sen University
- PhD, 2004, HongKong University of Science and Technology



Prof. Dongyi Xu
Peking University; School of life Sciences

Current Research Interest

- Systemically analyzing protein complexes in DNA repair
- Investigating the functions of new proteins in maintenance of genomic stability
- Searching new targets of anti-cancer drug

Education

- BSc, 1999, Peking University
- PhD, 2005, Peking University
- PostDoc, 2011, NIA/NIH



Dr. Tom Kinzel
Bayer; Head of Innovation Center China, Drug Discovery

Tom received his PhD in organic chemistry from the University of Göttingen in 2008 where he studied reaction mechanism and selectivities using a combined computational and experimental approach. He then moved to the Massachusetts Institute of Technology as postdoctoral fellow, working on Palladium-catalyzed cross-coupling reactions. Tom joined Bayer in 2011 and worked for three years as lab head in medicinal chemistry in Wuppertal. In 2014, he moved to Berlin and became the assistant of the head of the Drug Discovery organization. Since January 2016, Tom is the head of the Innovation Center China, which identifies opportunities, aligns, and manages research collaboration projects between Bayer Drug Discovery scientists and outstanding Chinese academic institutions as well as CROs. In 2001/2002, Tom spent one year in China, studying Chinese at Nanjing University and completing an internship in molecular biology at the Chinese Academy of Sciences in Shanghai.